Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Humboldt University Berlin, Berlin, Germany

Survival: 23.4 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Adriamycin
Country: Germany
City/State/Province: Berlin
Hospital: Humboldt University Berlin
Journal: Link
Date: 1/2005

Patients: This Phase III study involved 93 women with metastatic breast cancer. The patients were randomly placed into two groups: Group A had 48 patients (median age 48.9 years). All patients had at least one metastatic site, which included lung, liver, and bone. All patients had not received chemotherapy prior to treatment.

Treatment: For Group A, the treatment involved a "conventional chemotherapy regiment" with two agents: doxorubicin and paclitaxel.

Toxicity: In Group A, grade 3-4 toxicities included: reduced white blood cell count, thrombocytopenia, nausea/vomiting, and anemia.

Results: The median overall survival was 23.4 months for Group A and 26.9 months for Group B.

Support: Bristol-Myers Squibb (Munich, Germany), Amgen Pharma (Munich, Germany), and Wyeth (Lederle, Germany) provided financial support for this trial. Bristol-Myers Squibb manufactures and markets cyclophosphamide, etoposide and paclitaxel. Amgen manufactures and markets filgrastim, which was used in this study to boost white blood cell production.

Correspondence: Peter Schmid, MD

E-mail to a Friend Email Physician More Information